On February 9, 2016, I had the pleasure to host a panel discussion of the Austrian Association of Education and Science Journalists with Norbert Bischofberger and Josef Penninger at the Presseclub Concordia. This is how I presented the event to the club members:
„’Going public‘ is an ambiguous term. It can mean seeking the attention of a lay audience in order to raise the awareness and attention for science in general and basic research in particular. It can also mean selling shares that were formerly privately held to new investors for the first time, otherwise known as an initial public offering (IPO). The two scientists Norbert Bischofberger and Josef Penninger know a lot about going public in every sense of the word. At the Klubabend on Tuesday, February 9, 2016, 6 pm, they will discuss the advantages and the pitfalls of the interaction between science and society, research and business.
How do scientists perceive the role of journalists? What are their expectations? How well should journalists be informed before contacting a scientist? What can journalism contribute to the dissemination of science? What does the disruption of the classic publication model in favor of open access mean for the dissemination of science? How should scientists and journalists handle the diminishing function of the traditional bottleneck of science journals?
Dr. Norbert Bischofberger is the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead, located in Foster City (California), with 7.500 employees and a turnover of $ 24.5 bn one of the largest biopharmaceutical companies worldwide (NASDAQ: GILD). Dr. Josef Penninger is Scientific Director of the Vienna based IMBA and Wittgenstein-Laureate 2014.“